In contrast to other cell types, vascular smooth muscle cells modify their phenotype in response to external signals. NADPH oxidase 4 (Nox4) is critical for maintenance of smooth muscle gene expression; however, the underlying mechanisms are incompletely characterized. Using smooth muscle α-actin (SMA) as a prototypical smooth muscle gene and transforming growth factor-β (TGF-β) as a differentiating agent, we examined Nox4-dependent signaling. TGF-β increases Nox4 expression and activity in human aortic smooth muscle cells (HASMC). Transfection of HASMC with siRNA against Nox4 (siNox4) abolishes TGF-β-induced SMA expression and stress fiber formation. siNox4 also significantly inhibits TGF-β-stimulated p38MAPK phosphorylation, as well as that of its substrate, mitogen-activated protein kinase-activated protein kinase-2 (MK-2). Moreover, the p38MAPK inhibitor SB-203580 nearly completely blocks the SMA increase induced by TGF-β. Inhibition of either p38MAPK or NADPH oxidase-derived reactive oxygen species impairs the TGF-β-induced phosphorylation of Ser103 on serum response factor (SRF) and reduces its transcriptional activity. Binding of SRF to myocardin-related transcription factor (MRTF) is also necessary, because downregulation of MRTF by siRNA abolishes TGF-β-induced SMA expression. Taken together, these data suggest that Nox4 regulates SMA expression via activation of a p38MAPK/SRF/MRTF pathway in response to TGF-β.
the mechanisms responsible for re-expression of VSMC contractile genes are incompletely understood.
We previously established that NADPH oxidase 4 (Nox4) is critical for the maintenance of differentiation marker gene expression in VSMC [2] . Other studies have shown that Nox4 regulates smooth muscle-specific gene expression induced by transforming growth factor β (TGF-β) in stem cells [3] , fibroblasts [4] and pulmonary artery smooth muscle cells [5, 6] . In addition, Nox4 and its activator Poldip2, appear to regulate stress fiber formation, conceivably by activating RhoA [7] . However, almost nothing is known about the mechanisms by which reactive oxygen species (ROS) derived from Nox4 affect expression of these genes and ultimately drive stress fiber formation. Indeed, very little is known about any downstream effectors of Nox4.
TGF-β is a potent inducer of SMA gene expression in many cell types, including VSMC [8, 9] , mesangial cells [10, 11] , fibroblasts [4, 6, 12, 13] and stem cells [3] . In addition to Nox4, signaling through multiple pathways has been implicated in TGF-β-induced gene expression, which can be divided in Smad-dependent and Smad-independent pathways (reviewed in [14, 15] ). Phosphorylation of Smad3 by TGF-β is important for the induction of SMA [4, 12, 16] . Recently, other non-Smad pathways have also been shown to be important for the full expression of SMA by TGF-β. Thus, Deaton et al. [17] demonstrated that p38 mitogen activated protein kinase (p38MAPK) is important for TGF-β-induced SMA expression in rat pulmonary arterial smooth muscle cells, modulating the activity of the transcription factors MEF2, SRF and GATA. Furthermore, pharmacological inhibition of p38MAPK inhibits the increase of SMA in the epithelial-mesenchymal transition (EMT) induced by TGF-β [16, 18] . Recently, Liu et al. [19] showed that mitogen-activated protein kinase-activated-protein kinase-2 (MK-2), a substrate of p38MAPK, participates in the upregulation of SMA by TGF-β in fibroblasts. Of note, previous work has shown that p38MAPK activation is exquisitely sensitive to ROS [20, 21] .
Another non-Smad pathway that has been linked to TGF-β-induced SMA expression is the small GTPase RhoA and its effectors. Indeed, RhoA kinase [5] and mammalian Diaphanous (mDia) [22] [23] [24] regulate the release of myocardin-related transcription factor (MRTF) from the G-actin pool by inducing stress fiber formation, and SMA expression via Serum Response Factor (SRF) activation [25, 26] . This is of particular interest because Nox4 has been shown to activate RhoA [7] as well as SRF expression [2] . SRF was originally discovered as a transcription factor implicated in c-fos and c-egr expression induced by serum [27, 28] ; however, it soon became apparent that it was also an important regulator of smooth muscle specific genes. Promoters of these genes contain CArG boxes [29] [30] [31] , which bind to SRF in the presence of the co-activators myocardin and MRTF [32] [33] [34] [35] . In addition, SRF can undergo several modifications that alter its function. For example, phosphorylation of Ser162 [36] and Thr159 [37] on SRF has been shown to decrease SRF-dependent SMA expression, whereas phosphorylation of Ser103 enhances its activity [38, 39] .
Our previous work in serum-deprived VSMC suggested a link between Nox4, ROS, SRF and differentiation marker gene expression [2, 7] , but there are no studies examining the upstream signaling pathways by which Nox4-derived ROS regulate smooth muscle-specific gene expression. Here, using SMA as a prototypical smooth muscle gene and TGF-β as our inducing stimulus, we report that Nox4-mediated activation of p38MAPK leads to the phosphorylation and activation of SRF, increases SRF-dependent transcriptional activity, and increases SMA expression.
MATERIALS AND METHODS

Materials
TGF-β was obtained from R&D Systems (Minneapolis, MN). The following antibodies were used for Western blot: SMA, calponin and α-tubulin (Sigma, St. Louis, MO); phospho-p38MAPK, p38MAPK, phospho-MK2 and phospho-SRF (Cell Signaling Technology, Beverly, MA); SRF (Clone 2-313, Millipore, Billerica, MA); and MRTFA (C-19) (Santa Cruz Biotechnology, Santa Cruz, CA). For immunocytochemistry, AlexaFluor468 Phalloidin was purchased from Invitrogen (Carlsbad, CA), secondary anti-mouse was from Jackson Immunoresearch (West Grove, PA) and DAPI was from Sigma (St. Louis, MO). The inhibitor of p38MAPK (SB-203580) was purchased from Enzo Life Sciences and the MRTF/SRF activity inhibitor (CCG-1423) was from Cayman (Ann Arbor, MN).
Cell culture
Human aortic smooth muscle cells (HASMC) were obtained from Invitrogen (Carlsbad, CA). Cells were cultured as recommended by the manufacturer and used between passages 5-7.
Western blot
HASMC were lysed in Hunter's buffer (25 mM HEPES, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM Na-pyrophosphate, 10 mM NaF, 0.1 mM Na-orthovanadate, 1% Na deoxycholate, 1% Triton X-100, 0.1% SDS, 10% Glycerol, and protease inhibitors), as described previously (7) . Proteins were separated using SDS-PAGE and transferred to nitrocellulose membranes, blocked, and incubated with appropriate primary antibodies. Proteins were detected by ECL (Amersham). Band intensity was quantified by densitometry using ImageJ 1.38 software.
RNA isolation and Real Time Quantitative PCR (RT-qPCR)
Total RNA was purified from cells using the RNeasy kit, as recommended in the manufacturer's protocol. First-strand cDNA synthesis was performed using total RNA, random dodecamer primers, and Superscript III reverse transcriptase (Invitrogen), according to the enzyme supplier's instructions. cDNAs obtained were additionally purified using microbiospin 30 columns (BioRad). Quantification of nox4, 18S rRNA, and SMA was performed by amplification of HASMC cDNA using the LightCycler real-time thermocycler (Roche). Primers and amplification conditions for 18S, and nox4 and SMA were used as previously published [4] . Copy number was calculated by the instrument software from standard curves of genuine templates.
Luciferase assay
HASMC (1×10 6 ) were transfected with 2 μg of pGL4.34 SRF.RE Vector (Promega) and R1-Renilla using a Nucleofector (Amaxa Biosystems) set to the U25 program. SRF.RE vector is designed to measure specifically the Serum Response Element that it is present in smooth muscle genes. After transfection, HASMC were allowed to attach in complete media overnight, and were incubated for 24 h in serum free medium before treatment with TGF-β (2 ng/ml) for 24 h. Firefly luciferase (SRF) and Renilla reniformis luciferase activities were determined using a Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol in a TD20/20 Luminometer (Turner Designs, Sunnyvale,CA). Luciferase activity (SRF) was normalized to Renilla activity.
Immunofluorescence microscopy
HASMC were plated on collagen I-coated glass coverslips (BD) and either serum deprived for 24 h or transiently transfected with siRNA for 72 h. The cells were prepared as described previously [7] , followed by incubation with Phalloidin (F-actin), DAPI (nuclei), or primary antibody to SMA for 1 h. For SMA, cells were incubated with a secondary antibody linked to Rhodamine. Vectashield mounting medium (Vector Laboratories, Inc.) was used for all confocal experiments. Images were acquired with a Zeiss LSM 510 META Laser Scanning Confocal Microscope System using a Plan-Apo 420782-9900 63x oil objective lens (numerical aperture: 1.40) and Zeiss ZEN acquisition software. To validate the specificity of the antibodies, controls with no primary antibody were performed and showed no fluorescence. Single label controls were also performed in all multiple labeling experiments (not shown). When comparing cells from different treatment groups, all image threshold settings of the confocal microscope remained constant.
siRNA studies
HASMC were transfected with 25 nM small interference RNA against Nox4 (siNox4) [2] or with the All-Star negative control siRNA (Qiagen) using Oligofectamine (Invitrogen) in OPTI-MEM (Gibco). Cells were then cultured in serum-free media for 72 h prior to treatments. For siRNA against MRTFA, 1×10 6 cells were nucleotransfected with 200 pmol of siRNA against MRTFA [40] or All Star negative control siRNA (Quiagen) using the U-025 program (Amaxa). After attaching, cells were then cultured in serum-free media for 48 h prior to treatments.
NADPH oxidase activity
Membrane samples from HASMs were prepared as described previously [41] . HASMs were harvested, washed twice with ice-cold 50 mM phosphate buffer (PBS), scraped, centrifuged at 400g (10 min), and resuspended in 1 ml of lysis buffer (50 mM phosphate (treated for 2h with 5g/100ml Chelex-100 and filtered) containing the protease inhibitors aprotinin (10 μg/ ml), leupeptin (0.5 μg/ml), pepstatin (0.7 μg/ml), and PMSF (0.5 mM) (pH 7.4)). Cells were sonicated (power: 4 watts, using Microson 2425 from Misonix Inc; Farmingdale, NY, USA) for 10 s on ice and centrifuged at 28,000g for 15 min at 4°C. The membrane pellet was resuspended in 150 μl of lysis buffer and protein concentration was measured using the Bradford microplate method.
Twenty μg of protein were added to 1 mM 1-hydroxy-3-carboxy-pyrrolidine (CPH), 200μM NADPH, and 0.1 mM diethylenetriaminepentaacetic acid (DTPA) in a total volume of 100μL of Chelex-treated PBS. CPH is a nitrone spin trap that provides quantitative measurements of O 2
•− radicals with high sensitivity. ESR spectroscopy was used for quantitative measurements of O 2 •− production. In duplicate samples, NADPH was omitted. Superoxide formation was assayed as NADPH-dependent, SOD-inhibitable formation of 3carboxy-proxyl (CP • ). Samples were placed in 50 μl glass capillaries (Corning, New York). The ESR spectra were recorded using an EMX ESR spectrometer (Bruker) and a super-high Q microwave cavity. The ESR instrumental settings were as follows: field sweep, 50 G; microwave frequency, 9.78 GHz; microwave power, 20 mW; modulation amplitude, 2 G; conversion time, 656 ms; time constant, 656 ms; 512 points resolution and receiver gain, 1 × 10 5 . Kinetics were recorded using a 1312ms conversion time and a 5248ms time constant by monitoring the ESR amplitude of the low-field component of the ESR spectrum of CP • . Superoxide dismutase (50 U/ml) added directly to the sample inhibited 95-98% of CP • production.
Statistical analysis
Results are expressed as mean ± S.E.M. from at least three independent experiments. Statistical significance was assessed using analysis of variance (ANOVA), followed by Bonferroni's Multiple Comparison post-hoc test. A value of p<0.05 was considered significant.
RESULTS
TGF-β induces Nox4 expression and activity in HASMC
Previous studies have demonstrated an increase in Nox4 mRNA and protein levels after TGF-β treatment in other cell types [3, 6] . To determine if TGF-β upregulates Nox4 in HASMC, cells were treated with TGF-β (2 ng/ml) for different times and Nox4 mRNA expression was measured by RT-qPCR ( Fig.1 ). TGF-β increases Nox4 mRNA levels as early as 4 h, reaching maximum induction at 24 h (20±4-fold increase over control).
Nox4 activity is in large part regulated by its level of expression [21] ; thus, we evaluated if TGF-β also induces its activity. It has been reported that the major detectable ROS generated by Nox4 is H 2 O 2 [42, 43] . We therefore measured NADPH-dependent H 2 O 2 production in membrane fractions of HASMC treated with TGF-β for 24h. We observed a 1.9±0.2-fold increase in H 2 O 2 production, but only a small change in superoxide production in response to TGF-β at 24 hours ( Fig. 2 ). To confirm that this increase is due to Nox4 activity, HASMC were transfected with siRNA against Nox4 and were then treated with TGF-β for 24 h. siNox4 completely blocked TGF-β-induced, NADPH-dependent H 2 O 2 production ( Fig. 2) , confirming that Nox4 is responsible for the ROS produced in response to TGF-β. In order to determine the specificity of siNox4, we measured its effect on Nox4 and Nox5 mRNA levels, the two most highly expressed homologues in these cells [44] . While Nox4 mRNA was dramatically reduced (siCtr, 3390±380* vs. siNox4, 810±210 copies per μl of cDNA, * p< 0.05, n=3), no changes in Nox5 expression were observed in HAVSMC transfected with siNox4 (siCtr, 6324±583 vs. siNox4, 5908±373 copies per μl of cDNA, n.s, n=3).
Nox4 is required for TGF-β induced SMA expression and stress fiber formation
To investigate whether the activation of Nox4 is required for TGF-β induction of SMA, HASMC were incubated with TGF-β for 24 h and SMA expression was measured by western blot. Treatment with TGF-β caused an increase in SMA mRNA and protein expression in HASMC ( Fig. S1 ). Moreover, this increase in SMA expression is Nox4dependent, since transfection with siNox4 completely blocks TGF-β-induced SMA expression ( Fig. 3A ). In order to analyze whether the effect of Nox4 is confined to SMA expression, we also measured calponin (CNN) expression and observed similar results ( Fig.  S2A ).To confirm that NADPH oxidase-derived ROS are required for this effect, we preincubated HASMC with diphenylene iodonium (DPI, 10 μM), a flavin-containing oxidase inhibitor, N-Acetylcysteine (NAC, 10 mM), an antioxidant or ebselen (10 μM), a glutathione peroxidase mimetic, prior to treatment with TGF-β for 24 h (2 ng/ml). We have previously shown that these concentrations of inhibitors block ROS production in VSMC ( [45, 46] and Fig. S3B ). All pretreatments inhibit TGF-β-induced SMA expression ( Fig. S3A) . Together with the siNox4 data, these experiments indicate that Nox4-derived ROS mediate TGF-βinduced SMA expression in HASMC.
To examine the subcellular fate of increased SMA, we used immunocytochemistry. As expected, TGF-β treatment increases the number of SMA-containing stress fibers, an effect that is completely blocked by siNox4 ( Fig. 3B ).
p38MAPK mediates TGF-β-induced SMA expression and stress fiber formation
In some cell types, p38MAPK is activated by TGF-β with slow kinetics [16] . Our group and others have shown that p38MAPK is a target of ROS [20, 47, 48] . Thus, we investigated whether Nox4 modulates p38MAPK activation by TGF-β. Our results show that a 24 h treatment with TGF-β increases p38MAPK activation (213±15% vs siCtr), and that this activation is partially blunted in siNox4-transfected HASMC (130±19% vs siCtr) ( Fig.4) . This inhibition is also reflected in a reduction in activation of MK-2, a substrate of p38MAPK (Fig. S4A ).
Next, we tested the hypothesis that p38MAPK activation is required for TGF-β-induced SMA expression. HASMC were preincubated with SB-203580 (10 μM), a specific p38MAPK inhibitor that we have previously shown to prevent p38MAPK activation in VSMC [20] , and then treated with 2 ng/ml TGF-β for 24 h. Inhibition of p38MAPK blocks the induction of SMA expression by TGF-β ( Fig. 5A) . Similar results were obtained for CNN expression (Fig. S2B ). Together, these data suggest that p38MAPK is a downstream effector of Nox4-mediated SMA and expression in this system.
To confirm the role of p38MAPK in SMA incorporation into stress fibers after TGF-β treatment, we examined stress fiber distribution using immunocytochemistry in cells treated with inhibitors of these pathways. Fig. 5B shows that pretreatment with SB-203580 blocks TGF-β-induced SMA-containing stress fiber formation. These results suggest that p38MAPK is primarily important in regulating SMA expression.
Nox4/p38MAPK regulates SRF phosphorylation and SRF/MRTF-dependent activation of the SMA promoter
Although transcriptional control of SMA is complex, SRF binding to CArG box elements in its promoter has been shown to be required for SMA induction [8] . Phosphorylation of Ser103 (pSRF-S103) by the p38MAPK downstream effector MK-2 [38] is one mechanism by which SRF activity is regulated. Because TGF-β induction of SMA in HASMC is dependent on p38MAPK, we investigated the ability of TGF-β to both activate MK-2 and phosphorylate SRF. As shown in Fig. Fig. 6A and S4B, a 24 h treatment with TGF-β increased phosphorylation of both of these proteins, an effect that was inhibited by SB-203580. Additionally, we observed a moderate increase in total SRF expression in TGFβ-stimulated cells (140±10% vs Ctr), which was completely blocked by preincubation with SB-203580 ( Fig. 6A) . To determine the role of Nox4 in these responses, we studied whether siNox4 could modulate SRF phosphorylation or expression. Consistent with the ability of Nox4 to activate p38MAPK, TGF-β-treated HASMC transfected with siNox4 showed a decrease in pSRF-S103 compared with the control. We also observed a decrease in SRF expression, as reported previously [2] (Fig. 6B ).
To determine whether ROS production and/or phosphorylation of SRF by p38MAPK/MK-2 are important for SRF activity, we used a luciferase assay. HASMC were transfected with SRE luciferase reporter plasmid and then stimulated with TGF-β. We observed a 2-fold increase in SRF activity in response to TGF-β, which was completely blocked by preincubation with DPI and SB-203580 ( Fig. 7) . No changes in basal SRF activity were found after treatment with these inhibitors (data not shown).
Finally, because MRTF is a coactivator of SRF that induces SMA expression [32, 49] , we investigated the potential participation of MRTF in TGF-β-induced SRF-mediated induction of SMA and calponin expression in HASMC using siRNA against MRTFA, . HASMC were transfected with siRNA MRTFA and then treated with TGF-β for 24 h. siMRTFA nearly abolished the effect of TGF-β on SMA ( Fig. 8) and CNN (Fig. S2C) expression. Additionally, we preincubated HAVSMC with a pharmacological inhibitor of MRTF/SRF activity, CCG-1432 (0.1-1 μM) [50] and then treated them with TGF-β for 24 h. Similar to the results obtained with siRNA against MRTFA, CCG-1432 inhibits SMA expression induced by TGF-β in a dose-dependent manner, reaching a maximum effect at 1 μM ( Fig  S5A) .
DISCUSSION
The cytokine TGF-β has many biological effects, both physiological and pathophysiological. Due to its ability to induce smooth muscle genes, it has been associated with the progression of different pathologies such as pulmonary fibrosis [6] and diabetic nephropathy [51] . However, TGF-β is also required to maintain a normal, contractile phenotype in SMC. Among of all smooth muscle genes, SMA is the most abundant in SMC and the best characterized [52] . Here, we dissect a mechanism by which TGF-β utilizes ROS derived from Nox4 to upregulate SMA and calponin, and identify p38MAPK and SRF as two key downstream targets of Nox4 (Fig. 7) .
Although TGF-β was originally linked to the activation of the Smad pathway [53, 54] , recent studies have shown that TGF-β controls a number of Smad-independent signaling pathways as well [14] . We observed that in HASMC, p38MAPK activity was increased after 24 h of TGF-β treatment and that this was mediated by Nox4. While the exact mechanism by which Nox4 activates p38MAPK is unknown, we speculate that ROS produced by Nox4 may reduce the activity of the associated phosphatase, as has been shown for many other phosphatases (reviewed in [55] ). Of particular relevance to p38MAPK, Hou et al. [56] recently showed that ROS production induces the oxidation of mitogen kinase phosphatase-1 (MKP-1), a phosphatase with activity against MAPKs. Similarly, Kim et al. [57] have shown that ROS production inhibits protein phosphatases 1 and 2A (PP1/2A) and MKP3, leading to an induction of phosphorylation of ERK1/2. Another possibility it is that the induction of Nox4 leads to a decrease in the expression, or an increase in the degradation, of the phosphatase implicated in the dephosphorylation of p38MAPK. Recently, we have demonstrated that H 2 O 2 induces IP 3 receptor degradation through proteasome activation in rat aortic VSMCs [58] , raising the possibility that this is a universal mechanism by which H 2 O 2 can affect signaling. Finally, it is possible that the upstream kinase of p38MAPK, TAK-1 [16, 59, 60] , is a direct or indirect target of Nox4. Future experiments will be required to distinguish between these possibilities.
Several studies have shown that the level of SMA protein expression is largely dependent on the regulation of SMA mRNA expression [4, 17] . SMA gene transcription is controlled by multiple transcriptional factors, both positive such as Smad3 [4] , myocardin [61] , and MRTF [32, 62] , and negative such as KLF4 [9, 63] and YB-1 [64] . SRF is considered a dual function transcription factor: depending on which co-activator it binds, SRF can stimulate differentiation or proliferation. Thus, Wang et al. [61] showed that TGF-β induces the binding of SRF with myocardin, which stimulates the expression of smooth muscle genes, whereas PDGF stimulates binding of SRF with Ternary Complex Factor (TCF), which induces the expression of proliferative genes and inhibits differentiation marker genes. Our results showed that MRTF is critical for TGF-β-induced SMA expression, since transfection with siMRTFA almost completely prevents the increase of SMA by TGF-β in HAVSMC. This result agrees with previous articles reporting that a decrease of MRTF by siRNA inhibits the expression of SMA induced by sphingosine 1-phosphate [32, 65] , TGF-β [32] or FBS [40] . Additionally, a pharmacological inhibitor of SRF activity, CCG-1432, almost completely abolished TGF-β-induced SMA expression. Interestingly, preincubation of CCG-1432 induced a reduction of Nox4 mRNA expression, even in TGF-β-stimulated cells (Fig. S5B ). Whether this effect is specific for MRTF inhibition, or is due to other potential targets of CCG-1432 such as myocardin or RhoA [50] requires further investigation. Here, we have described for the first time that p38MAPK activity is likely an important upstream activator of MRTF/SRF by TGF-β, since SRF activity is completely blocked by a p38MAPK inhibitor.
Besides binding to different cofactors, SRF can undergo several modifications that alter its affinity for DNA. Thus, phosphorylation by PKA or PKCα on Ser162 or Thr159 decreases the affinity of SRF [36, 37] , whereas the phosphorylation by p38MAPK on Ser103 increases it [38] . The role of SRF-Ser103 phosphorylation in the gene expression profile is controversial. Originally this phosphorylation was discovered in response to serum [39, [66] [67] [68] and found to promote the binding of SRF to TCF, which decreases smooth muscle gene expression [61] . In contrast, Heidenreich et al. [38] observed that p38MAPK kinase induces SRF phosphorylation at Ser 103 and promotes smooth muscle gene expression [61] . These contradictory results raise the possibility that phosphorylation at Ser103 increases SRF activity, but that its effects on gene expression are determined by its cofactor. Our own data demonstrate that SRF activity is increased by TGF-β via a ROSsensitive mechanism that involves p38MAPK-dependent phosphorylation of SRF on Ser103 and apparently increases its interaction with MRTF. This results in an increase in expression of smooth muscle-specific genes, including SMA and calponin. However, based on our results we cannot rule out the possibility that p38MAPK alters the activity of other transcription factors as well. Thus, Deaton et al. [17] showed that p38MAPK is required for the activation of GATA and MEF2 by TGF-β. Moreover, Kamaraju and Roberts [69] demonstrated that the activation of p38MAPK by TGF-β is necessary for the proper activation of Smad3. However, our results show that Smad2/3 phosphorylation induced by TGF receptor type II kinase is unmodified for siNox4 transfection or preincubation with p38MAPK inhibitor (unpublished observations), indicating that Smad activation is unlikely a target of p38MAPK and Nox4 in our model. Futhermore, Masszi et al. [70] recently showed that Smad3 acts a negative modulator of MRTFA activity in fibroblast. .Alternatively, p38MAPK might induce the degradation of SMA repressors such as KLF4 [63] . More work is necessary to investigate these additional pathways.
Our results show a slight increase in SRF expression after TGF-β stimulation as has been previously described [71] . Of note, in our experiment we used 24 hours of TGF-β incubation, which probably is not long enough to observe a large increase in SRF expression. However, when we compare the levels of SRF in TGF-β-treated with cells transfected with siNox4 or preincubated with p38MAPK inhibitor, we observe a reduction in SRF expression. Previous reports have shown that SRF regulates its own expression [49, 72] . Because Nox4 and p38MPAK are necessary for the increase in TGF-β-induced SRF activity, we suggest that longer term treatment with TGF-β is likely to induce SRF expression. We propose that Nox4 and p38MAPK are also upstream of the increase of SRF expression induced by TGF-β, suggesting a positive feedback loop.
Using immunocytochemistry, we observed that SMA localizes in actin fibers in TGF-βtreated cells (Fig. 3B) . A previous article showed that the reorganization of actin in stress fibers precedes the formation of SMA-containing fibers during myofibroblast spreading [73] . Stress fiber formation is regulated by RhoA activity and focal adhesion turnover (reviewed in [74] ). RhoA, in turn, controls stress fiber formation by ROCK and mDia1 [22, 75] . It is worth noting that siNox4 reduced basal RhoA activity and nearly abolished stress fibers (unpublished observations), and that we have previously observed a loss of focal adhesions in cells treated with siNox4 [7] . Recently Goffin et al. [76] showed that an increase of focal adhesion size allows the cell to generate SMA-stress fibers, which increases its contractile capacity. Our result suggests that Nox4 could be active at two levels: it may regulate SMA gene expression and it may regulate focal adhesion (FA) formation/ maturation, thus influencing stress fiber assembly.
In summary, we found that (i) Nox4 is critical for TGF-β-mediated SMA expression; [56] p38MAPK activation by TGF-β plays an important role in SMA expression; (iii) Nox4 controls p38MAPK activity; and (iv) the increase in SRF activity by TGF-β is mediated by ROS production and p38MAPK activity. Moreover, we observed that Serine 103 phosphorylation of SRF by p38MAPK/MK2 can play an important role in SMA expression by TGF-β ( Fig.9 ). Since previous reports have shown that SMA is essential for the contractile stress fibers, our data suggest that p38MAPK activation by Nox4 might provide a mechanism by which the cells regulate their phenotype and therefore their responsiveness to contractile or proliferative factors. This work was supported by NIH grants HL38206 and HL095070.
ABBREVIATIONS
DPI
Diphenylene iodonium
HASMC
Human aortic vascular smooth muscle cells
MK-2
Mitogen-activated protein kinase-activated-protein kinase-2 
MRTF
TGF-β
Transforming growth factor-β Stimulation of HASMC with TGF-β upregulates Nox4, increasing H 2 O 2 production. H 2 O 2 stimulates the activity of p38MAPK/MK2, which phosphorylates SRF at Serine 103 (S103). SRF and MRTF, as a cofactor, upregulate SMA and SRF expression.
